Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasms, Neuroblastoma

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Locoregional Recurrence

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2 Negative Breast Cancer

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

Carcinoma, Ovarian Epithelial, Breast Neoplasms

Brain Neoplasms, Glioblastoma, Glioma

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Leiomyosarcoma, Liposarcoma, Sarcoma

HER2 Negative Breast Cancer Not Immediately Operated

Clinical Trials

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NoLEEta

FELINE

NEPENTHE

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Match Mel

RaPhLRR

DISCORDANT

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

ESMART

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Ribociclib and Bicalutamide in AR+ TNBC

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

LEADER

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

MegaMOST

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

ARIADNE

ADAPTcycle

SAFIR 03

SELECT

BRAVE-Cyclin

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

HARMONIA

CHARGE

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

CALHYS